Given the high prevalence of treatment-resistant depression and the long delays in finding
effective treatments via trial and error, valid biomarkers of treatment outcome with the ability …

Repetitive transcranial magnetic stimulation (rTMS) and intermittent theta-burst stimulation
(iTBS) are evidenced-based treatments for patients with major depressive disorder (MDD) …

Major depression is a leading cause of disability; however, a subset of patients do not
experience sufficient relief from existing first-line treatments 1 or have trouble tolerating the …

Repetitive transcranial magnetic stimulation (rTMS), an established treatment for treatment-
resistant depression, may hold promise as a personalized medicine approach for the …

Explainable artificial intelligence holds a great promise for neuroscience and plays an
important role in the hypothesis generation process. We follow-up a recent machine learning …

Major depressive disorder (MDD) is a pleomorphic illness originating from gene x
environment interactions. Patients with differing symptom phenotypes receive the same …

Repetitive transcranial magnetic stimulation (rTMS) has demonstrated efficacy in major
depressive disorder (MDD), although clinical outcome is variable. Change in the resting …

Electroencephalography (EEG) is a non-invasive method to identify markers of treatment
response in major depressive disorder (MDD). This review's objectives were the following …

Background: Biomarkers that predict clinical outcomes in depression are essential for
increasing the precision of treatments and clinical outcomes. The electroencephalogram …

There is a growing need for optimizing treatment selection and response prediction in
individuals with major depressive disorder (MDD). Prior investigations have shown that …